VANCOUVER, British Columbia, May 28, 2024 Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner clinical data in.
Days after I wrote about the Guardian Ad Litem (GAL) role for litigants here in the R.B. v. E.A.C. matter, another case was released on a similar issue: In The Matter of A.H. In.